Idexx Laboratories (IDXX) financial statements
- FY2025 revenue
- $4.3B▲ +10.4%
- FY2025 net income
- $1.1B▲ +19.3%
- FY2025 diluted EPS
- $13.08▲ +22.6%
- FY2025 free cash flow
- $1.1B▲ +30.8%
Idexx Laboratories income statement
| USD millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Revenue | 4,304 | 3,898 | 3,661 |
| Gross profit | 2,660 | 2,379 | 2,190 |
| Operating income | 1,360 | 1,128 | 1,097 |
| Pretax income | 1,324 | 1,110 | 1,061 |
| Net income | 1,059 | 888 | 845 |
| Diluted earnings per share | 13.08 | 10.67 | 10.06 |
Idexx Laboratories balance sheet
| USD millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Cash and cash equivalents | 180 | 288 | 454 |
| Total assets | 3,351 | 3,293 | 3,260 |
| Total liabilities | 1,745 | 1,698 | 1,775 |
| Total equity | 1,605 | 1,595 | 1,485 |
| Long-term debt | 375 | 450 | 623 |
Idexx Laboratories cash flow statement
| USD millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Operating cash flow | 1,182 | 929 | 907 |
| Capital expenditure | -125 | -121 | -134 |
| Free cash flow (derived) | 1,057 | 808 | 773 |
| Share repurchases | -1,217 | -837 | -72 |
Quarterly highlights
| USD millions | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 |
|---|---|---|---|---|
| Period ended | 30 Jun 2026 | 31 Mar 2026 | 31 Dec 2025 | 30 Sep 2025 |
| Revenue (derived) | 1,217 | 1,141 | 1,091 | 1,105 |
| Operating income (derived) | 426 | 363 | 316 | 355 |
| Net income (derived) | 338 | 278 | 248 | 275 |
| Diluted earnings per share | 4.27 | 3.47 | n/a | 3.40 |
| Operating cash flow (derived) | 347 | 266 | 356 | 402 |
| Total assets | 3,442 | 3,385 | 3,351 | 3,387 |
Idexx Laboratories major shareholders
| Holder | Share of class | Shares | Filed |
|---|---|---|---|
| BlackRock, Inc. | 9.4% | 7,599,078 | 17 April 2025 |
| Vanguard Capital Management | 7.5% | 5,976,472 | 30 April 2026 |
| Vanguard Portfolio Management | 5.0% | 3,974,472 | 30 October 2026 |
Idexx Laboratories 10-K and SEC filings
| Filed | Form | Type | Description |
|---|---|---|---|
| 2 November 2026 | 8-K | Current report | FORM 8-K |
| 4 August 2026 | 10-Q | Quarterly report | Quarterly report |
| 4 August 2026 | 8-K | Current report | FORM 8-K |
| 15 May 2026 | 8-K | Current report | Current report |
| 5 May 2026 | 10-Q | Quarterly report | Quarterly report |
| 5 May 2026 | 8-K | Current report | FORM 8-K |
| 26 March 2026 | 8-K | Current report | FORM 8-K |
| 20 February 2026 | 10-K | Annual report | Annual report |
Common questions
What was Idexx Laboratories' revenue in fiscal 2025?
Idexx Laboratories reported $4.3 billion in revenue for fiscal 2025, the year ended 31 December 2025, up 10.4% from fiscal 2024.
What was Idexx Laboratories' net income in fiscal 2025?
Idexx Laboratories reported net income of $1.1 billion for fiscal 2025, the year ended 31 December 2025, up 19.3% from fiscal 2024. Diluted earnings per share were $13.08.
What was Idexx Laboratories' free cash flow in fiscal 2025?
Idexx Laboratories had $1.1 billion in free cash flow in fiscal 2025. Operating cash flow was $1.2 billion and capital expenditure was $125 million.
What were Idexx Laboratories' total assets at the end of fiscal 2025?
Idexx Laboratories reported total assets of $3.4 billion at the end of fiscal 2025, the year ended 31 December 2025.
How much Idexx Laboratories history does each plan include?
Free covers the last 3 fiscal years of annual figures. Basic covers the last 10 fiscal years, annual and quarterly. Pro covers the full history, with first reported values and as of dates.
Get these figures through the API
5,000 free requests every month. No card needed.